Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Florio G et al. | The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. | 2000 | AIDS | pmid:10853974 |
Nowak P et al. | Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection. | 2003 | AIDS Res. Hum. Retroviruses | pmid:12581512 |
Sklar EM | Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play? | 2006 | AJNR Am J Neuroradiol | pmid:16971594 |
Bargalló N et al. | Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. | 2000 | AJNR Am J Neuroradiol | pmid:10730638 |
Bartynski WS et al. | Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. | 2001 Nov-Dec | AJNR Am J Neuroradiol | pmid:11733324 |
Bartynski WS et al. | Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. | 2004 | AJNR Am J Neuroradiol | pmid:14970028 |
Bartynski WS et al. | Posterior reversible encephalopathy syndrome after solid organ transplantation. | 2008 | AJNR Am J Neuroradiol | pmid:18272559 |
Schuuring J et al. | Severe tacrolimus leukoencephalopathy after liver transplantation. | 2003 Nov-Dec | AJNR Am J Neuroradiol | pmid:14625238 |
Oliverio PJ et al. | Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. | 2000 | AJNR Am J Neuroradiol | pmid:10954277 |
Appignani BA et al. | Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. | 1996 | AJR Am J Roentgenol | pmid:8623651 |
Landy J and Hart AL | Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336680 |
Hirai F et al. | Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336690 |
BenÃtez C et al. | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589580 |
Schmidt KJ et al. | Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. | 2013 | Aliment. Pharmacol. Ther. | pmid:23121200 |
Yamamoto S et al. | Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. | 2008 | Aliment. Pharmacol. Ther. | pmid:18549460 |
O'Leary JG | Editorial: tacrolimus-how low can you go? | 2017 | Aliment. Pharmacol. Ther. | pmid:28589579 |
Schwrer H et al. | Pantoprazole and cyclosporine or tacrolimus. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284790 |
Nakase H et al. | Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy. | 2011 | Aliment. Pharmacol. Ther. | pmid:21434949 |
Nakase H et al. | Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis? | 2011 | Aliment. Pharmacol. Ther. | pmid:21198700 |
Mehta SJ et al. | Review article: strategies for the management of chronic unremitting ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23718288 |